Compare Micron Technology, Inc. (MU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Twist Bioscience Corp — how do they compare? Micron Technology, Inc. trades at $1,052 (market cap $1.17T), while Twist Bioscience Corp trades at $154.5 (market cap $10.08B). The key difference: Micron Technology, Inc. is far larger — about 116.1× Twist Bioscience Corp's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Twist Bioscience Corp for 27 Days on average.
| MU | TWST | |
|---|---|---|
Market Cap | $1.17T | $10.08B |
Volume | 29,425,906 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $1.21K | $205.00 |
52-Week Low | $181.60 | $25.45 |
Typical Hold Time | 48 Days | 27 Days |
Enterprise Value | $1.13T | $10.01B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,088, up 4.06% today, reflecting strong momentum amid a bullish technical outlook. The stock shows robust fundamentals with a P/E of 14.64, net income margin of 63.8%, and three consecutive quarterly earnings beats. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus favoring Buy ratings (82.85%) and a $1,590 price target. Key risks include cyclical memory pricing and slowing growth projections, but institutional sentiment and cash flow trends support upside potential for investors seeking AI-driven semiconductor exposure.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
